SAPPHIRE THERAPEUTICS, INC. NEWS

02/12/2008
Sapphire Therapeutics Promotes Suzan Allen to Vice President Clinical Operation


10/30/2007
Sapphire Therapeutics Licenses Ghrelin Antagonist Program from Novo Nordisk for Development of Obesity Treatment


08/13/2007
Sapphire Therapeutics Announces Promotions and New Appointment to Management Team


04/26/2007
Sapphire Therapeutics, Inc. to Present Results from Anamorelin Phase 2 Cachexia/Anorexia Studies at ASCO and ENDO Annual Meetings in June Ono Plans Japanese Phase 1 Stud


10/26/2006
Sapphire Therapeutics, Inc. Licenses Novel Drug to Ono Pharmaceuticals in Japan, Korea and Taiwan for the Treatment of Cancer Anorexia/Cachexi


09/19/2006
Sapphire Therapeutics, Inc. Licenses Ghrelin Mimetic From Novo Nordisk
Ipamorelin to Enter Phase II for Postoperative Ileus


08/25/2006
Sapphire Therapeutics, Inc. Expands Drug Development Team; New CEO, Board Appointment


01/17/2006
Sapphire Therapeutics, Inc. Appoints New Director and Scientific Advisory Board to Support Oncologic and Metabolic Pipeline Development


01/06/2006
Sapphire Therapeutics, Inc. Builds Drug Development Team Through New Hires and Promotion


12/15/2005
Sapphire Therapeutics, Inc.’s Oral Ghrelin Mimetic Shows Potential for Treating Cancer Anorexia/Cachexia


10/18/2005
Wallstreet Reporter Interviews Sapphire Therapeutics


10/05/2005
Rejuvenon Corporation. changes name to Sapphire Therapeutics; Closes on second tranche of Series B financing


07/20/2005
Rejuvenon’s RC-8800 for Prostate Cancer Enters Human Testing
RC-1291 Ghrelin Mimetic Starts Phase II in Cachexia


01/10/2005
Rejuvenon’s RC-1291 Ghrelin Mimetic Receives Fast Track Designation from FDA for Cancer Anorexia/Cachexia


06/23/2004
Rejuvenon Raises $37 Million in Series B Venture Financing; New Board Members Names